MAYNE PHARMA GROUP LIMITED (MYX)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

MYX

MYX - MAYNE PHARMA GROUP LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -4.14
Index: ASX300 | ALL-ORDS

Mayne Pharma is an Australian pharmaceuticals development and manufacturing company with facilities in Australia and the US. It also provides development and manufacturing services to global clients. It listed in 2007.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$5.20

10 Jul
2025

-0.050

OPEN

$5.29

-0.95%

HIGH

$5.29

294,162

LOW

$5.17

OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CSL . CUV . DXB . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MSB . MVP . NEU . NUZ . NXS . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SNT . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS

- No Record -

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx-218.8
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx388.4 M
Book Value Per Share xxxxxxxxxxxxxxx559.0
Net Operating Cash Flow xxxxxxxxxxxxxxx-9.6 M
Net Profit Margin xxxxxxxxxxxxxxx-43.41 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx-30.98 %
Return on Invested Capital xxxxxxxxxxxxxxx-29.16 %
Return on Assets xxxxxxxxxxxxxxx-14.10 %
Return on Equity xxxxxxxxxxxxxxx-30.98 %
Return on Total Capital xxxxxxxxxxxxxxx-13.25 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-17.5 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx4 M
Long Term Debt xxxxxxxxxxxxxxx35 M
Total Debt xxxxxxxxxxxxxxx39 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx152 M
Price To Book Value xxxxxxxxxxxxxxx0.84

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx20.9 M
Capex % of Sales xxxxxxxxxxxxxxx5.37 %
Cost of Goods Sold xxxxxxxxxxxxxxx229 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx237 M
Research & Development xxxxxxxxxxxxxxx20 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

0
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Wilsons

05/03/2025

3

Downgrade to Market Weight from Overweight

$7.40

42.31%

Wilsons lifts Mayne Pharma's target price to $7.40 from $5.95 to align with Cosette Pharma's bid price. Rating is lowered to Market Weight from Overweight.

The broker notes Mayne's 1H25 result was pre-flagged but the composition was better than expected. The broker was surprised with how effective the channel strategy worked for the Dermatology business

The broker raised FY25 revenue and EBIDTA estimates following the 7% beat in the 1H. The analyst sees the Cosette bid as a fair price for the company.

FORECAST
Wilsons forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -7.80 cents.
Wilsons forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -3.30 cents.
Access Extra Coverage Research History >

MYX STOCK CHART

FNArena News on MYX

1
Next Week At A Glance – 23-27 Jun 2025

Jun 20 2025 - Weekly Reports
2
Next Week At A Glance – 26-30 May 2025

May 23 2025 - Weekly Reports
3
Australian Broker Call *Extra* Edition – May 15, 2025

May 15 2025 - Daily Market Reports
4
Australian Broker Call *Extra* Edition – Apr 27, 2025

Apr 28 2025 - Daily Market Reports
5
Australian Broker Call *Extra* Edition – Apr 15, 2025

Apr 16 2025 - Daily Market Reports

Latest Pharmaceuticals & Biotech/Lifesciences News

1
The Enigma Surrounding Clinuvel

Jul 03 2025 - Small Caps
2
Rudi’s View: CSL & NextDC

May 08 2025 - Rudi's View
3
Behring Margin Outlook Still Main Game For CSL

Feb 13 2025 - Australia
4
Dr Boreham’s Crucible: Arovella Therapeutics

Aug 29 2024 - Small Caps
5
ResMed’s Margin Upside Excites

Aug 07 2024 - Australia
6
Dr Boreham’s Crucible: Aroa Biosurgery

Jul 29 2024 - Small Caps
7
CSL Shares Breaking Free

Jul 23 2024 - Technicals
8
Dr Boreham’s Crucible: SDI

Jul 19 2024 - Small Caps
9
‘Defensive’ Pharmaceutical Wholesalers In Focus

Jul 18 2024 - Australia
10
Twists And Turns Of Telix And Australian Biotech

Jul 10 2024 - Small Caps